Trial of Roflumilast Cream for Chronic Plaque Psoriasis

2020116 citationsJournal Article

Authors

Mark Lebwohl · Probity Medical Research

Kim Papp · Probity Medical Research

Linda Stein Gold · Henry Ford Hospital

Melinda Gooderham · Probity Medical Research

Leon Kircik · Probity Medical Research

Zoe Draelos · Dermatology Consulting Services

Steven Kempers ·

Abstract

Roflumilast cream administered once daily to affected areas of psoriasis was superior to vehicle cream in leading to a state of clear or almost clear at 6 weeks. Longer and larger trials are needed to determine the durability and safety of roflumilast in psoriasis. (Funded by Arcutis Biotherapeutics; ARQ-151 201 ClinicalTrials.gov number, NCT03638258.).

Topics & Keywords

Psoriasis: Treatment and Pathogenesis Dermatology and Skin Diseases Asthma and respiratory diseases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 383, Issue 3, pp. 229-239

DOI: 10.1056/nejmoa2000073

Field-Weighted Citation Impact: 5.61